Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38

Benzinga Newsdesk www.benzinga.com Positive 83.5%

Neg 0% Neu 0% Pos 83.5%

Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.